Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Deffered Revenue (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 99.44% to $1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1000.0, a 99.44% decrease, with the full-year FY2024 number at $97000.0, down 66.44% from a year prior.
  • Non-Current Deffered Revenue was $1000.0 for Q3 2025 at Vivos Therapeutics, down from $5000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $533000.0 in Q1 2024 to a low of $1000.0 in Q3 2025.
  • A 5-year average of $236235.3 and a median of $250000.0 in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 158.04% in 2023, then tumbled 99.44% in 2025.
  • Vivos Therapeutics' Non-Current Deffered Revenue stood at $343000.0 in 2021, then plummeted by 67.35% to $112000.0 in 2022, then soared by 158.04% to $289000.0 in 2023, then tumbled by 66.44% to $97000.0 in 2024, then crashed by 98.97% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Non-Current Deffered Revenue are $1000.0 (Q3 2025), $5000.0 (Q2 2025), and $22000.0 (Q1 2025).